Verastem, Inc. (2VSA.F)
EUR 4.28
(-35.15%)
EUR 4.28
(-35.15%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 92.34 Million USD | 93.76% |
| 2022 | 47.65 Million USD | 125.84% |
| 2021 | 21.1 Million USD | -45.99% |
| 2020 | 39.07 Million USD | -71.66% |
| 2019 | 137.87 Million USD | -9.85% |
| 2018 | 152.93 Million USD | 376.34% |
| 2017 | 32.1 Million USD | 183.33% |
| 2016 | 11.33 Million USD | 6.65% |
| 2015 | 10.62 Million USD | 7.51% |
| 2014 | 9.88 Million USD | 26.46% |
| 2013 | 7.81 Million USD | 218.07% |
| 2012 | 2.45 Million USD | -96.58% |
| 2011 | 71.8 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 77.31 Million USD | -16.27% |
| 2024 Q2 | 65.73 Million USD | -14.98% |
| 2023 Q1 | 66.69 Million USD | 39.94% |
| 2023 Q3 | 71.81 Million USD | 4.07% |
| 2023 Q4 | 92.34 Million USD | 28.59% |
| 2023 Q2 | 69 Million USD | 3.47% |
| 2023 FY | 92.34 Million USD | 93.76% |
| 2022 Q2 | 46.51 Million USD | 7.24% |
| 2022 Q4 | 47.65 Million USD | -1.17% |
| 2022 FY | 47.65 Million USD | 125.84% |
| 2022 Q1 | 43.37 Million USD | 105.55% |
| 2022 Q3 | 48.22 Million USD | 3.67% |
| 2021 Q2 | 35.68 Million USD | 4.06% |
| 2021 FY | 21.1 Million USD | -45.99% |
| 2021 Q3 | 16.22 Million USD | -54.54% |
| 2021 Q4 | 21.1 Million USD | 30.09% |
| 2021 Q1 | 34.29 Million USD | -12.24% |
| 2020 Q2 | 84.15 Million USD | -1.19% |
| 2020 Q1 | 85.17 Million USD | -38.22% |
| 2020 Q4 | 39.07 Million USD | -55.6% |
| 2020 FY | 39.07 Million USD | -71.66% |
| 2020 Q3 | 87.99 Million USD | 4.56% |
| 2019 Q2 | 169.23 Million USD | 9.25% |
| 2019 Q1 | 154.9 Million USD | 1.29% |
| 2019 FY | 137.87 Million USD | -9.85% |
| 2019 Q4 | 137.87 Million USD | -19.41% |
| 2019 Q3 | 171.08 Million USD | 1.09% |
| 2018 Q3 | 75.54 Million USD | 64.04% |
| 2018 Q2 | 46.05 Million USD | 54.23% |
| 2018 Q1 | 29.85 Million USD | -7.0% |
| 2018 FY | 152.93 Million USD | 376.34% |
| 2018 Q4 | 152.93 Million USD | 102.45% |
| 2017 Q4 | 32.1 Million USD | 44.93% |
| 2017 Q3 | 22.15 Million USD | 62.81% |
| 2017 Q2 | 13.6 Million USD | -13.75% |
| 2017 FY | 32.1 Million USD | 183.33% |
| 2017 Q1 | 15.77 Million USD | 39.23% |
| 2016 Q2 | 6.35 Million USD | -3.65% |
| 2016 Q4 | 11.33 Million USD | 71.49% |
| 2016 FY | 11.33 Million USD | 6.65% |
| 2016 Q1 | 6.59 Million USD | -37.92% |
| 2016 Q3 | 6.6 Million USD | 3.98% |
| 2015 FY | 10.62 Million USD | 7.51% |
| 2015 Q4 | 10.62 Million USD | -6.99% |
| 2015 Q3 | 11.42 Million USD | 9.47% |
| 2015 Q2 | 10.43 Million USD | 3.34% |
| 2015 Q1 | 10.09 Million USD | 2.18% |
| 2014 Q3 | 9.07 Million USD | 11.14% |
| 2014 Q1 | 6.4 Million USD | -18.09% |
| 2014 FY | 9.88 Million USD | 26.46% |
| 2014 Q2 | 8.16 Million USD | 27.53% |
| 2014 Q4 | 9.88 Million USD | 8.94% |
| 2013 Q3 | 5.72 Million USD | 8.61% |
| 2013 Q1 | 3.41 Million USD | 38.79% |
| 2013 FY | 7.81 Million USD | 218.07% |
| 2013 Q4 | 7.81 Million USD | 36.53% |
| 2013 Q2 | 5.27 Million USD | 54.55% |
| 2012 Q3 | 3.21 Million USD | -2.34% |
| 2012 Q4 | 2.45 Million USD | -23.65% |
| 2012 Q2 | 3.29 Million USD | 8.75% |
| 2012 Q1 | 3.03 Million USD | -95.78% |
| 2012 FY | 2.45 Million USD | -96.58% |
| 2011 Q4 | 71.8 Million USD | 3278.96% |
| 2011 FY | 71.8 Million USD | 0.0% |
| 2011 Q3 | 2.12 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| BioNTech SE | 2.76 Billion EUR | 96.655% |
| CureVac N.V. | 271.53 Million EUR | 65.991% |
| Biotest Aktiengesellschaft | 945.4 Million EUR | 90.232% |
| Biotest Aktiengesellschaft | 945.4 Million EUR | 90.232% |
| BRAIN Biotech AG | 47.92 Million EUR | -92.692% |
| Formycon AG | 387.61 Million EUR | 76.176% |
| Heidelberg Pharma AG | 21.01 Million EUR | -339.456% |
| Medigene AG | 10.65 Million EUR | -767.08% |